Women's Health - Clinical Trials banner

Women's Health - Clinical Trials

Ovarian cancer:

  • Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First-Line Platinum-Based Chemotherapy NCT01844986
  • Maintenance with Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer (NOVA) NCT01847274
  • A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab (MSB0010718C) in combination with and/or following chemotherapy in patients with previously untreated epithelial ovarian cancer (JAVELIN 100) NCT02718417
  • A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors NCT01609556
  • A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients with Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA) NCT02354586
  • A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin or Pembrolizumab in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, or Endometrial Cancer NCT02606305
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (PRIMA) NCT02655016
  • A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant / refractory ovarian cancer (JAVELIN 200) NCT02580058
  • A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor α-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (FORWARD 1) NCT02631876
  • Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy  (LIGHT) NCT02983799
  • A Phase 1 Study of ALKS 4230 Administered Intravenously a Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors(ALKERMES) NCT02799095
  • A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. NCT03836352
  • Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas NCT02503423
  • ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) NCT03522246
  • A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) NCT03740165
  • A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O). NCT03737643
  • A randomized, double-blind, phase 3 comparison of platinum-based therapy with tsr-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage iii or iv nonmucinous epithelial ovarian cancer NCT03602859
  • A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors NCT03134638

Endometrial cancer:

  • A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (GARNET) NCT02715284
  • A Phase II, Open label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK 4827) in Recurrent Endometrial Cancer NCT03016338
  • A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475)Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) NCT03884101

Cervical cancer: 

  • VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA VACCINE) Delivered IM Followed by Electroporation with Cellectra®-5p For The Treatment Of Biopsy-Proven CIN 2/3 Or CIN 3 With Documented HPV 16 Or 18 NCT01304524
  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIAL NCT01414608
  • Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy 

Other: 

  • Cervical and Self-Sample in Screening (CASSIS) Study: Diagnostic Performance of Molecular HPV Testing with the Eve Medical Self-Collection System© for Detecting Cervical Intraepithelial Neoplasia NCT02397252
  • DOvEE project: Diagnosing Ovarian & Endometrial Cancer Early NCT02296307
  • DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Uterus, Tubes and Ovaries NCT02288676


For more information regarding clinical trials, please contact us.